全文获取类型
收费全文 | 12223篇 |
免费 | 1007篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 134篇 |
儿科学 | 447篇 |
妇产科学 | 418篇 |
基础医学 | 1800篇 |
口腔科学 | 188篇 |
临床医学 | 1577篇 |
内科学 | 2012篇 |
皮肤病学 | 176篇 |
神经病学 | 1192篇 |
特种医学 | 350篇 |
外科学 | 1433篇 |
综合类 | 225篇 |
一般理论 | 16篇 |
预防医学 | 1361篇 |
眼科学 | 207篇 |
药学 | 747篇 |
中国医学 | 38篇 |
肿瘤学 | 948篇 |
出版年
2023年 | 93篇 |
2022年 | 124篇 |
2021年 | 363篇 |
2020年 | 244篇 |
2019年 | 321篇 |
2018年 | 334篇 |
2017年 | 249篇 |
2016年 | 320篇 |
2015年 | 314篇 |
2014年 | 455篇 |
2013年 | 580篇 |
2012年 | 888篇 |
2011年 | 948篇 |
2010年 | 482篇 |
2009年 | 462篇 |
2008年 | 740篇 |
2007年 | 730篇 |
2006年 | 698篇 |
2005年 | 674篇 |
2004年 | 655篇 |
2003年 | 624篇 |
2002年 | 554篇 |
2001年 | 165篇 |
2000年 | 133篇 |
1999年 | 165篇 |
1998年 | 138篇 |
1997年 | 105篇 |
1996年 | 89篇 |
1995年 | 88篇 |
1994年 | 83篇 |
1993年 | 79篇 |
1992年 | 89篇 |
1991年 | 101篇 |
1990年 | 87篇 |
1989年 | 77篇 |
1988年 | 77篇 |
1987年 | 50篇 |
1986年 | 64篇 |
1985年 | 64篇 |
1984年 | 74篇 |
1983年 | 59篇 |
1982年 | 59篇 |
1981年 | 44篇 |
1980年 | 32篇 |
1979年 | 42篇 |
1978年 | 36篇 |
1974年 | 38篇 |
1973年 | 52篇 |
1972年 | 39篇 |
1967年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献2.
3.
Valerie Iles 《Health care analysis》2016,24(2):105-118
This paper takes a somewhat slant perspective on flourishing and care in the context of suffering, death and dying, arguing that care in this context consists principally of ‘acts of work and courage that enable flourishing’. Starting with the perception that individuals, society and health care professionals have become dulled to death and the process of dying in Western advanced health systems, it suggests that for flourishing to occur, both of these aspects of life need to be faced more directly. The last days of life need to be ‘undulled’. Reflections upon the experiences of the author as carer and daughter in the face of her mother’s experience of death are used as basis for making suggestions about how care systems and professionals might better assist people in dealing with ‘the most grown up thing’ humans ever do, which is to die. 相似文献
4.
5.
6.
7.
8.
9.
10.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献